These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 29044863)

  • 41. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.
    Jeon MJ; Chun SM; Kim D; Kwon H; Jang EK; Kim TY; Kim WB; Shong YK; Jang SJ; Song DE; Kim WG
    Thyroid; 2016 May; 26(5):683-90. PubMed ID: 26980298
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Establishment and molecular characterization of a human ovarian clear cell carcinoma cell line (FDOV1).
    Jiang W; Ye S; Xiang L; Yang W; He T; Pei X; Guo L; Yang H
    J Ovarian Res; 2018 Jul; 11(1):58. PubMed ID: 29986747
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mutation analysis of CTNNB1 gene and the ras pathway genes KRAS, NRAS, BRAF, and PIK3CA in eyelid sebaceous carcinomas.
    Kwon MJ; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY
    Pathol Res Pract; 2017 Jun; 213(6):654-658. PubMed ID: 28551389
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic impact of molecular profiles and molecular signatures in clear cell ovarian cancer.
    Schnack TH; Oliveira DNP; Christiansen AP; Høgdall C; Høgdall E
    Cancer Genet; 2023 Nov; 278-279():9-16. PubMed ID: 37567101
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical analysis and literature review of a case of ovarian clear cell carcinoma with PIK3CA gene mutation: A case report.
    Farah AM; Gu S; Jia Y
    Medicine (Baltimore); 2022 Sep; 101(37):e30666. PubMed ID: 36123851
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
    Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
    J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype.
    Takenaka M; Köbel M; Garsed DW; Fereday S; Pandey A; Etemadmoghadam D; Hendley J; Kawabata A; Noguchi D; Yanaihara N; Takahashi H; Kiyokawa T; Ikegami M; Takano H; Isonishi S; Ochiai K; Traficante N; Gadipally S; Semple T; Vassiliadis D; Amarasinghe K; Li J; Mir Arnau G; Okamoto A; Friedlander M; Bowtell DDL;
    Clin Cancer Res; 2019 Jul; 25(13):3962-3973. PubMed ID: 30967419
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tetraspanin 1 promotes endometriosis leading to ovarian clear cell carcinoma.
    Shin HY; Yang W; Chay DB; Lee EJ; Chung JY; Kim HS; Kim JH
    Mol Oncol; 2021 Apr; 15(4):987-1004. PubMed ID: 33331115
    [TBL] [Abstract][Full Text] [Related]  

  • 49. ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.
    Berns K; Caumanns JJ; Hijmans EM; Gennissen AMC; Severson TM; Evers B; Wisman GBA; Jan Meersma G; Lieftink C; Beijersbergen RL; Itamochi H; van der Zee AGJ; de Jong S; Bernards R
    Oncogene; 2018 Aug; 37(33):4611-4625. PubMed ID: 29760405
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing: A Korean Gynecologic Oncology Group study (KGOG 3047).
    Sa JK; Kim J; Kang S; Kim SW; Song T; Shim SH; Choi MC; No JH; Song JY; Kim D; Kim YM; Kim JH; Lee JW
    Int J Cancer; 2022 Oct; 151(7):1086-1097. PubMed ID: 35666535
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden.
    Anglesio MS; Bashashati A; Wang YK; Senz J; Ha G; Yang W; Aniba MR; Prentice LM; Farahani H; Li Chang H; Karnezis AN; Marra MA; Yong PJ; Hirst M; Gilks B; Shah SP; Huntsman DG
    J Pathol; 2015 Jun; 236(2):201-9. PubMed ID: 25692284
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expression and significance of ARID1A mRNA in endometriosis- associated ovarian cancer.
    Wang Q; Wang L; L Y; Ding X; Liu A
    J BUON; 2017; 22(5):1314-1321. PubMed ID: 29135119
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multiregion whole-genome sequencing depicts intratumour heterogeneity and punctuated evolution in ovarian clear cell carcinoma.
    Yin X; Bi R; Ma P; Zhang S; Zhang Y; Sun Y; Zhang Y; Jing Y; Yu M; Wang W; Tan L; Di W; Zhuang G; Cai MC
    J Med Genet; 2020 Sep; 57(9):605-609. PubMed ID: 31862729
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Suppression of ARID1A associated with decreased CD8 T cells improves cell survival of ovarian clear cell carcinoma.
    Jung US; Min KW; Kim DH; Kwon MJ; Park H; Jang HS
    J Gynecol Oncol; 2021 Jan; 32(1):e3. PubMed ID: 33185044
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Distinct gene expression profiles associated with clinical outcomes in patients with ovarian clear cell carcinoma and high-grade serous ovarian carcinoma.
    Zhou H; Liu Q; Shi X; Liu Y; Cao D; Yang J
    J Ovarian Res; 2020 Apr; 13(1):38. PubMed ID: 32295618
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clonal Expansion and Diversification of Cancer-Associated Mutations in Endometriosis and Normal Endometrium.
    Suda K; Nakaoka H; Yoshihara K; Ishiguro T; Tamura R; Mori Y; Yamawaki K; Adachi S; Takahashi T; Kase H; Tanaka K; Yamamoto T; Motoyama T; Inoue I; Enomoto T
    Cell Rep; 2018 Aug; 24(7):1777-1789. PubMed ID: 30110635
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma.
    Maeda D; Mao TL; Fukayama M; Nakagawa S; Yano T; Taketani Y; Shih IeM
    Int J Mol Sci; 2010; 11(12):5120-8. PubMed ID: 21614196
    [TBL] [Abstract][Full Text] [Related]  

  • 58. GLS1 is a protective factor in patients with ovarian clear cell carcinoma and its expression does not correlate with ARID1A-mutated tumors.
    Clemente V; Hoshino A; Shetty M; Nelson A; Erickson BK; Baker R; Rubin N; Khalifa M; Weroha SJ; Lou E; Bazzaro M
    Cancer Res Commun; 2022 Aug; 2(8):784-794. PubMed ID: 36082022
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A clearer view on ovarian clear cell carcinoma.
    De Pauw A; Naert E; Van de Vijver K; Philippe T; Vandecasteele K; Denys H
    Acta Clin Belg; 2022 Aug; 77(4):792-804. PubMed ID: 34404331
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Involvement of Chromatin Remodeling Genes and the Rho GTPases
    Arildsen NS; Jönsson JM; Bartuma K; Ebbesson A; Westbom-Fremer S; Måsbäck A; Malander S; Nilbert M; Hedenfalk IA
    Front Oncol; 2017; 7():109. PubMed ID: 28611940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.